Pulmonary Vein Isolation Using an Occluding Cryoballoon for Circumferential Ablation: Feasibility, Complications, and Short-term Outcome
Overview
Authors
Affiliations
Aims: To assess safety, feasibility and short term outcome of pulmonary vein (PV) isolation in paroxysmal atrial fibrillation (AF) with a cryoballoon.
Methods: We consecutively treated 57 patients with a double lumen 23 or 28 mm cryoballoon. The acute results, complications and follow-up over the first three months were analysed, using a comprehensive and intensive follow-up period.
Results: During 57 procedures, 185 of 220 targeted PV's were successfully isolated using the cryoballoon (84%) (balloon group, 33 patients). In 33 veins (15%) an additional segmental isolation (hybrid group, 24 patients) was necessary with a standard cryocatheter to achieve isolation. The average procedure times were respectively 211 +/- 108 and 261 +/- 83 minutes (NS), the average fluoroscopy times 52 +/- 36 and 66 +/- 33 minutes (NS). The number of balloon applications did not differ between both groups: respectively a median 9 (4-18) and 10 (5-17) (NS). We observed four phrenic nerve paralysis after ablation of the right superior PV: two resolved immediately after cessation of the cryoenergy, one recovered after 3 months, one persisted up to 6 months. A daily transtelephonic rhythm recording showed a significant drop in mean AF burden from 24% to 10%, 8% and 5% during the three consecutive months of follow-up (p < 0.01 versus baseline). No differences were observed between the treatment groups. 34 patients (60%) were completely free from AF after a single procedure.
Conclusions: Balloon cryoablation of the pulmonary veins with additional segmental isolation if necessary, is a good approach for patients presenting with paroxysmal AF, showing a significant reduction in AF burden after a single procedure. The major complication seems to be phrenic nerve paralysis after ablation of the right superior PV, but this is potentially reversible over several months.
Effectiveness and Safety of Pulsed Field Ablation in Patients With Atrial Fibrillation.
Li R, Zhang X, Liu X, Gu Z, He J, Dong Y JACC Asia. 2025; 5(1):143-157.
PMID: 39896250 PMC: 11782097. DOI: 10.1016/j.jacasi.2024.09.014.
Song Q, Tan H, Yang B, Liu H, Fan C Rev Cardiovasc Med. 2024; 25(2):71.
PMID: 39077364 PMC: 11263141. DOI: 10.31083/j.rcm2502071.
Badertscher P, Weidlich S, Knecht S, Stauffer N, Krisai P, Voellmin G Europace. 2023; 25(12).
PMID: 38036293 PMC: 10751845. DOI: 10.1093/europace/euad329.
Progress in atrial fibrillation ablation during 25 years of Europace journal.
Boersma L, Andrade J, Betts T, Duytschaever M, Purerfellner H, Santoro F Europace. 2023; 25(9).
PMID: 37622592 PMC: 10451004. DOI: 10.1093/europace/euad244.
Michaelsen J, Parade U, Bauerle H, Winter K, Rauschenbach U, Mischke K J Interv Card Electrophysiol. 2022; 66(2):417-425.
PMID: 35962151 DOI: 10.1007/s10840-022-01331-9.